Innate Pharma Up 4% After FDA Lifts Partial Clinical Hold on Lacutamab
By Josh Beckerman Innate Pharma's American depositary receipts were recently up 4%, to $2.89, after the Food and Drug Administration lifted a partial...
Josh Beckerman Drug Administration Article Normal Biotechnology Services Cancer Drugs Healthcare Life Sciences
Source: marketwatch.com